Pain and Mood Disturbance Predict Patient Quality of Life

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

SAN DIEGO, California-Few studies have addressed the psychological effect of multiple myeloma, even though the disease has a discouraging prognosis and is often associated with significant pain. To learn more about this issue, Angela Poulos, RN, CNS, MS, a clinical nurse specialist in radiation oncology at the Mayo Clinic, examined the link between pain, mood disturbance, and quality of life (QOL) in these patients.

SAN DIEGO, California—Few studies have addressed the psychological effect of multiple myeloma, even though the disease has a discouraging prognosis and is often associated with significant pain. To learn more about this issue, Angela Poulos, RN, CNS, MS, a clinical nurse specialist in radiation oncology at the Mayo Clinic, examined the link between pain, mood disturbance, and quality of life (QOL) in these patients.

The study, presented at the Oncology Nursing Society’s 26th Annual Congress (abstract 146), was based on a survey mailed to 346 adult multiple myeloma patients identified from the Mayo Clinic database. The survey included the Brief Pain Inventory (short form), the Quality of Life Scale (cancer patient version), Profile of Mood States, and a demographic tool. A total of 206 patients responded.

On the pain scale, 80 respondents reported no pain, 65 said they had mild pain, 38 ranked their pain as moderate, and 22 reported severe pain. Quality-of-life scores ranged from 1.6 to 9.4, with a mean of 6.2 (higher scores correspond to a better quality of life). Older patients tended to report higher quality of life.

The researchers found significant associations between total pain and mood disturbance and between pain interference and mood disturbance. A joint predictive model composed of pain, mood disturbance factors, and demographic characteristics explained 74.6% of the variability in the quality-of-life scores.

The researchers concluded that pain remains untreated in many multiple myeloma patients, and that pain and mood disturbance scores are significant predictors of quality of life. The study also suggests that patients with multiple myeloma experience more mood disturbance than do patients with other types of cancer (based on data from other studies).

Pain control and treatment of psychosocial disturbance may improve quality of life in this patient group. The researchers recommend that adjunctive, multidisciplinary measures be explored, including support groups, counseling, and routine assessments of pain control in the outpatient setting.

Recent Videos
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
Related Content